Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04363346 · ClinicalTrials.gov registry record · Phase 1
Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia
A Phase 1 study, sponsored by Masonic Cancer Center, University of Minnesota.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04363346 is a Phase 1 study that has completed, run by Masonic Cancer Center, University of Minnesota. The registered enrollment target is 5 participants.
The verdict
NCT04363346, a Phase 1 study, has completed, sponsored by Masonic Cancer Center, University of Minnesota.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase I study with the primary objective of identifying the maximum tolerated dose (MTD) of FT516 using 3 dose-escalation strategies (number of doses and cell dose) for the treatment of coronavirus disease 2019 (COVID-19). This study provides initial estimates of safety and efficacy based on stable respiratory function, as well as, determining the feasibility for full-scale studies designed both for efficacy and safety.
Interventions
- DRUG FT516
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2020-05-14 |
| Est. Completion | 2021-02-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04363346
The ClinicalTrials.gov registry entry for NCT04363346 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Masonic Cancer Center, University of Minnesota, which has 249 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FT516 is the first listed.
NCT04363346 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04363346 about?
NCT04363346 is a clinical study titled "Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia". This is a Phase I study with the primary objective of identifying the maximum tolerated dose (MTD) of FT516 using 3 dose-escalation strategies (number of doses and cell dose) for the treatment of coronavirus disease 2019 (COVID-19). This study provides initial estimates of safety and efficacy based ...
What is the current status of trial NCT04363346?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2020-05-14. Estimated completion is 2021-02-18.
What interventions are being tested in trial NCT04363346?
The interventions under investigation include: FT516 (DRUG).
Who is sponsoring clinical trial NCT04363346?
This trial is sponsored by Masonic Cancer Center, University of Minnesota, which has 249 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.